Integration of Multi-Omics and Network Pharmacology Analysis Reveals the Mechanism of Qingchang Huashi Jianpi Bushen Formula in Repairing the Epithelial Barrier of Ulcerative Colitis
Open Access
- 1 May 2025
- journal article
- research article
- Published by Taylor & Francis in Journal of Inflammation Research
- Vol. ume 18, 6167-6189
Abstract
Purpose: Derivation of Qingchang Huashi formula, named Qingchang Huashi Jianpi Bushen (QCHS_JPBS) formula, has shown significant therapeutic effect on patients with ulcerative colitis (UC). In this study, the potential mechanism of QCHS_JPBS formula in repairing mucosal damage was explored from the perspective of intestinal stem cell (ISCs) differentiation, and potential targets of the QCHS_JPBS formula to improve UC were predicted using network pharmacology analysis. Methods: The therapeutic efficacy of QCHS_JPBS formula was evaluated in a mouse model of 2.5% dextran sulfate sodium (DSS) induced colitis. The effect of this formula on the ISC differentiation was evaluated using tissue transmission electron microscopy, immunofluorescence, and RT-qPCR. The cecal contents were subjected to 16s RNA sequencing analysis and non-target metabolomics analysis using LC-MS/MS. The fecal microbiota transplantation method verified the essential role of gut microbiota in promoting ISC differentiation and repairing mucosal damage. Results: The results indicated that QCHS_JPBS formula suppressed the inflammatory response and repaired the damaged intestinal epithelial barrier in DSS-induced colitis mice. QCHS_JPBS formula promoted ISC differentiation, particularly in the direction of goblet cells. QCHS_JPBS formula restored gut dysbiosis and regulated metabolic disorders in DSS-induced colitis mice. And then, the results of fecal microbiota transplantation indicated that QCHS_JPBS formula promoted differentiation of intestinal stem cells to repair mucosal damage through gut microbiota. Finally, a total of 79 active ingredients of QCHS_JPBS formula were identified based on LC-MS analysis and EGFR, STAT3, SRC, AKT1, and HSP90AA1 were considered as potential therapeutic UC targets of QCHS_JPBS formula based on network pharmacology analysis. Conclusion: The present study demonstrated that QCHS_JPBS formula promoted the differentiation of ISCs through gut microbiota to repair the damaged intestinal epithelial barrier in UC mice.Keywords
This publication has 47 references indexed in Scilit:
- Gut microbiota signatures in inflammatory bowel diseaseUnited European Gastroenterology Journal, 2023
- Recent advances in the treatment of IBD: Targets, mechanisms and related therapiesCytokine & Growth Factor Reviews, 2023
- Randomised clinical trial: Efficacy and safety of Qing-Chang-Hua-Shi granules in a multicenter, randomized, and double-blind clinical trial of patients with moderately active ulcerative colitisBiomedicine & Pharmacotherapy, 2021
- Anticancer activities of TCM and their active components against tumor metastasisBiomedicine & Pharmacotherapy, 2021
- Protective role of berberine on ulcerative colitis through modulating enteric glial cells–intestinal epithelial cells–immune cells interactionsActa Pharmaceutica Sinica B, 2020
- Network Pharmacology in Research of Chinese Medicine Formula: Methodology, Application and ProspectiveChinese Journal of Integrative Medicine, 2019
- Microbiota-Derived Lactate Accelerates Intestinal Stem-Cell-Mediated Epithelial DevelopmentCell Host & Microbe, 2018
- Gut Microbiota Regulation of Tryptophan Metabolism in Health and DiseaseCell Host & Microbe, 2018
- Indoleacrylic Acid Produced by Commensal Peptostreptococcus Species Suppresses InflammationCell Host & Microbe, 2017
- Role of epithelial cells in the pathogenesis and treatment of inflammatory bowel diseaseJournal of Gastroenterology, 2015